Anna L Groover - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Acta Neuropathologica Communications|November 21, 2013

Peripheral nervous system insulin resistance in ob/ob miceCaleb W Grote, Anna L Groover, Janelle M Ryals, et al.

Pain|August 13, 2013

Exercise-mediated improvements in painful neuropathy associated with prediabetes in miceAnna L Groover, Janelle M Ryals, Brianne L Guilford, et al.

JCO Precision Oncology|August 17, 2022

Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.

Cancer Discovery|December 17, 2017

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Acta Neuropathologica Communications|November 21, 2013

Peripheral nervous system insulin resistance in ob/ob miceCaleb W Grote, Anna L Groover, Janelle M Ryals, et al.

Pain|August 13, 2013

Exercise-mediated improvements in painful neuropathy associated with prediabetes in miceAnna L Groover, Janelle M Ryals, Brianne L Guilford, et al.

JCO Precision Oncology|August 17, 2022

Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.

Cancer Discovery|December 17, 2017

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.

Pageof 1